Pediatric Exclusivity: 36% Of Studies Lead To Significant New Labeling – FDA
Executive Summary
Studies conducted under the pediatric exclusivity program resulted in significant new dosing or safety information 36% of the time, according to a study published in the Journal of the American Medical Association Aug. 20
You may also be interested in...
FDA Pediatric Study Bill Clears Senate, Will Sunset With Exclusivity Grants
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
FDA Pediatric Rule “Usurps” Pediatric Exclusivity Law, Court Rules
The "command and control" approach of FDA's pediatric rule is "incompatible" with the Best Pharmaceuticals for Children Act, a Washington, D.C. federal judge ruled in striking down the agency reg
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011